Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00003293 | SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme | PHASE3 | COMPLETED | - | — | — | Feb 1, 1998 | May 1, 2001 | Sep 11, 2012 | 35 | United States, Canada |
| NCT00003775 | Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse | PHASE2 | COMPLETED | 60 | — | — | Dec 1, 1998 | May 1, 2006 | Sep 13, 2012 | 26 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| leflunomide | DRUG | - |
| procarbazine hydrochloride | DRUG | - |
DISEASE CHARACTERISTICS: Histologically proven refractory or recurrent supratentorial glioblastoma multiforme Bidimensionally measurable, enhancing residual disease by T1-weighted gadolinium-enhanced MRI required within 15 days prior to treatment Stable dose of corticosteroids required for at least ...